Presentations from five key opinion leaders on ProSense® cryoablation, including three independent breast cancer studies and one study on endometriosis, were showcased at the CIRSE 2025 Annual Meeting.
Three hands‑on training sessions for physicians interested in adopting ProSense® attracted strong attendance.
A dedicated CIRSE focus session on breast oncology highlighted the growing interest among interventional radiologists to expand their practice to treat breast‑cancer patients.
CAESAREA, Israel, Sept. 22, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM), the developer of a minimally invasive cryoablation platform that destroys tumors by freezing, announced its participation in the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Annual Meeting, held September 13‑17, 2025 in Barcelona, Spain. At the company’s exhibition booth, dozens of medical professionals observed live demonstrations of ProSense®, a single‑probe liquid‑nitrogen cryoablation system that is positioning itself as a next‑generation solution for interventional oncology, especially in breast cancer care.
“Our engagement at CIRSE was a clear indication that interventional radiologists are seeking advanced, clinically validated LN₂ cryoablation tools,” said IceCure’s Chief Executive Officer, Eyal Shamir. “We appreciate the investigators who have independently evaluated ProSense® and shared their positive outcomes at leading conferences.”
Key Highlights of ProSense® at CIRSE
- Three hands‑on device training sessions on cold ablation featuring ProSense® were conducted.
- Honorary lecture “Breaking barriers in breast cancer – cryoablation as the ultimate expression of interventional oncology’s de‑escalation philosophy,” delivered by Dr. Franco Orsi, Chief of Interventional Radiology, European Institute of Oncology, Milan, Italy. The talk traced the evolution of breast‑cancer treatment from radical mastectomy to organ‑preserving approaches and highlighted the PRECICE trial, which exclusively employs ProSense® for early‑stage breast cancer.
- The PRECICE study, sponsored by the Italian Ministry of Health, is enrolling 234 luminal‑type (A & B) patients over age 50, representing a broader cohort than IceCure’s earlier ICE3 trial.
- Three additional presentations on breast cancer were delivered during the “Focused Therapies for Challenging Tumors” session:
Comparative assessment of non‑surgical treatment strategies for breast cancer: evaluating cryoablation with hormonal therapy versus cryoablation alone and hormonal therapy alone in patients deemed ineligible for surgery – Dr. Sofia Baldi Giorgi, Radiology Resident, Careggi University Hospital, Florence, Italy. The prospective analysis of 83.4‑year‑old patients showed that combining cryoablation with hormonal therapy significantly reduced tumor size and residual disease versus hormonal therapy alone.
Cryoablation for small HR+ breast cancers in elderly patients: a prospective study of the first 55 patients treated at Institut Curie – Dr. Toulsie Ramthohul, Interventional Radiologist, Institut Curie Hospital, Paris, France. Outcomes demonstrated that ProSense® provided a safe, effective alternative to surgery for hormone‑receptor‑positive, HER2‑negative tumors in patients with a median age of 86.
Differential efficacy of cryoablation in breast tumor subtypes: ultrasound‑guided scar biopsy evaluation one year post‑treatment – Dr. Francesca Pugliese, Radiology Resident, Careggi University Hospital, Florence, Italy. In a cohort of 39 inoperable B5 lesions, cryoablation achieved complete radiologic response in low‑grade HR+ invasive ductal carcinoma, supporting its role as a breast‑conserving option.
- Presentation on the use of ProSense® for abdominal‑wall endometriosis by Dr. Ghizlane Touimi Benjelloun, CHU de Nîmes, France.
Efficacy and safety of percutaneous single‑probe cryoablation using liquid nitrogen in treatment of abdominal‑wall endometriosis – Prof. Julien Frandon, Director of Interventional Radiology, Nîmes University Hospital. The study reported a reduction in pain scores from an average of 8/10 to 1/10, with MRI confirming necrosis in 95 % of lesions and no visible scarring, positioning cryoablation as a minimally invasive alternative to surgery.
About ProSense®
ProSense® is a single‑probe, liquid‑nitrogen cryoablation system that creates large, lethal ice zones to eradicate both benign and malignant lesions in the breast, kidney, lung, and liver. Its portable design enables office‑based procedures, shortening recovery times, reducing postoperative pain, and minimizing surgical risks. By leveraging the thermodynamic properties of LN₂, ProSense® delivers rapid cooling cycles that achieve consistent ablation margins, a critical factor for oncologic efficacy.
Business and Technology Outlook
The global cryoablation market is projected to exceed $3 billion by 2030, driven by demand for minimally invasive cancer therapies and an aging patient population. IceCure’s ProSense® differentiates itself through a proprietary liquid‑nitrogen delivery system that avoids the logistical challenges of argon‑based platforms, reducing capital expenditures for clinics and enabling broader adoption in community hospitals. The company’s recent regulatory clearances in the United States, Europe, and Asia have expanded its addressable market, while ongoing reimbursement negotiations with Medicare and European health insurers are expected to improve payer acceptance.
Strategically, IceCure is leveraging its clinical data pipeline—exemplified by the PRECICE, ICE3, and endometriosis studies—to build a robust evidence base that supports expanded indications and accelerated regulatory approvals. Partnerships with leading academic centers and the company’s focus on training programs are accelerating physician adoption, a key driver of revenue growth in the early‑stage commercial rollout.
Competitive pressures remain, notably from argon‑based systems such as those from Galil Medical and Medtronic. However, ProSense®’s lower acquisition cost, ease of use, and demonstrated outcomes in elderly and comorbid patients provide a compelling value proposition. Continued investment in R&D to refine probe ergonomics and integrate real‑time thermal imaging could further strengthen IceCure’s market position.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid‑nitrogen cryoablation therapy systems for the treatment of benign and malignant tumors, with primary focus areas in breast, kidney, bone, and lung oncology. Its flagship ProSense® platform is commercially available across the United States, Europe, and Asia, offering clinicians a minimally invasive alternative to conventional surgical resection.
Forward‑Looking Statements
This release contains forward‑looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Statements regarding expectations, plans, and beliefs about ProSense® and IceCure’s business are subject to risks and uncertainties, including market acceptance, regulatory developments, reimbursement outcomes, and broader economic conditions. Actual results may differ materially from those projected. IceCure does not assume any obligation to update these statements, except as required by law.
SOURCE IceCure Medical
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/14268.html
